SG
TMBR

StoneX Group’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

StoneX Group’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-356
Closed -$2.14K – 669
2022
Q3 		$2.14K Buy
+356
New +$2.99K ﹤0.01% 338

Other funds holding TMBR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

StoneX Group's TMBR Position: Q4 2022 in Review

StoneX Group sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2022, closing a stake of 356 shares — an estimated $2.14K sold.

StoneX Group first reported a position in TMBR in Q3 2022 and held it in 1 quarter. The position peaked at $2.14K in Q3 2022. 11 funds tracked by Wall St. Rank hold TMBR as of Q4 2022.

  • StoneX Group reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • StoneX Group sold 356 Timber Pharmaceuticals, Inc. shares in Q4 2022, an estimated $2.14K.
  • StoneX Group first reported a position in Timber Pharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • StoneX Group's Timber Pharmaceuticals, Inc. position peaked at $2.14K in Q3 2022.
  • 11 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2022.

Based on StoneX Group's 13F filing for Q4 2022, filed 10 Feb 2023.